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Abstract 
Purpose: Noninvasive prenatal testing (NIPT) has changed the landscape of prenatal 
genetic evaluation. This novel test can be performed as early as 10 weeks gestation 
without risk of pregnancy complication and has evoked questions about its applicability, 
appropriate use, and patient response.  The purpose of this study was to evaluate patient 
decision-making processes about prenatal testing options as NIPT is integrated into the 
clinical realm.  Method: Prenatal patients who were offered NIPT during genetic 
counseling (N = 105) in three cities in South Carolina completed a survey to address the 
goals of this study. Results: The top five factors most frequently rated as important by 
participants were as follows:  (1) To be prepared if the baby had a disability (91%), (2) 
To avoid the risk of miscarriage (88%), (3) For reassurance the baby does not have a 
genetic condition (86%), (4) To obtain genetic information about the fetus as early as 
possible (81%), and (5) To have a test that provides more accurate information than other 
tests (77%).  Three factors were found to be significantly more important to participants 
who selected NIPT than to participants who did not:  (1) To obtain genetic information 
about the fetus as early as possible (p = .021), (2) To have a test that provides more 
accurate information than other tests (p = .025), and (3) To be prepared if the baby had a 
disability (p = .001).  In addition, a majority of participants (74%) felt consideration of 
termination if the baby had a chromosome condition was irrelevant to their decision.  
This factor was not an NIPT-selection factor, meaning participants who selected NIPT 
were not significantly more 
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likely to consider termination of an affected pregnancy important to their decision than 
participants who did not select NIPT.  Conclusions: Patients are faced with new 
decisions as NIPT is integrated into prenatal care.  This study evaluated the top five 
factors most frequently rated important by participants about their prenatal testing 
decision and identified three NIPT-selection factors.  While every patient should be 
counseled as a unique individual, the results from this study are observations that may 
help healthcare providers better understand patient perspective.  This study reveals five 
factors important to patient decision-making regarding prenatal testing; of these, three 
factors (obtaining genetic information about the fetus as early as possible, having a test 
that provides more accurate information than other tests, and being prepared if the baby 
had a disability) were significantly influential in patient selection of NIPT.   
 Keywords:  Noninvasive prenatal testing (NIPT), patient decision making, 
decision-making process, prenatal genetic testing 
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Chapter 1:  Background 
Since 2011, noninvasive prenatal testing (NIPT) has been clinically available to obtain 
near-diagnostic results for aneuploidy as early as 10 weeks gestation without risk of 
pregnancy complication (Wilson et al., 2012).  As this novel test integrates into the 
prenatal clinic, questions have been raised about its applicability, appropriate use, and 
how patients will respond.  To address these questions, it is important to consult accepted 
practice guidelines, research, and ethical statements.  An understanding of available 
prenatal testing and screening options is necessary to appreciate the conflict surrounding 
the role of NIPT in conjunction with or as a replacement for established prenatal tests.  
The following literature review attempts to provide an overview of prenatal testing and 
screening options currently available, the ethical implications of adding NIPT to these 
options as well as explore how patients make decisions about prenatal testing, and 
anticipatory patient response to NIPT.   
1.1 Prenatal Diagnostic Testing 
Prenatal diagnosis is typically offered by healthcare practitioners to patients 
whose pregnancies are at increased risk for chromosomal abnormalities or genetic 
disorders. Indications for diagnostic testing include:  a woman age 35 or older at delivery, 
an abnormal result on a screening test, a family history of a hereditary condition, or fetal 
anomalies seen on ultrasound.  While these indications prompt healthcare providers to 
discuss testing options with patients, diagnostic testing and ultrasound are available to all 
pregnant women (ACOG, 2007a).  Current diagnostic procedures, such as
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amniocentesis and chorionic villus sampling (CVS), use invasive methods to determine 
whether a fetus is affected with a genetic condition and provide highly sensitive results.   
Chorionic villus sampling is used to detect chromosomal aneuploidy in the first 
trimester between weeks 10 and 13.  Ultrasound guidance is required to remove 
trophoblastic tissue from the placenta with a catheter, either transcervically or 
transabdominally.  CVS results are obtained with 98%-99% accuracy, with a <1% chance 
of mosaicism and a <1% chance for maternal cell contamination.   Mosaicism in CVS 
cytogenetic analysis is often confined to the placenta, and amniocentesis is recommended 
for confirmation of the fetal karyotype (Collins & Impey, 2012).  The CVS procedure-
related chance of miscarriage approximates 0.5%-1% for both singleton and twin 
pregnancies (Wilson et al., 2012).  Other complications after CVS can involve vaginal 
spotting or bleeding, which may occur in up to 32.2% of transcervical procedures, and 
less often in a transabdominal approach.  The incidence of culture failure or amniotic 
fluid leakage after CVS is less than 0.5% (Milunsky, 2004).  CVS procedures performed 
before 10 weeks have been shown to increase the risk of fetal limb defects (World Health 
Organization, 1992).   
Amniocentesis is used to detect chromosomal aneuploidy in the second and third 
trimesters, starting at 15 weeks gestation.  Ultrasound guidance is required to insert a 
needle transabdominally into the amniotic sac to withdraw 20-30 cc of amniotic fluid, 
which contains fetal cells.  Amniocentesis results are obtained with 99.7%-99.9% 
accuracy.  The procedure-related chance of miscarriage approximates 1/300-1/500 
(ACOG, 2007b). Potential complications include a 1%-2% chance of vaginal spotting or 
amniotic fluid leakage and <0.1% chance of chorioamnionitis (Borgida, Mills, Feldman, 
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Rodis, & Egan, 2000).  Needle injuries to the fetus are very rare but have been reported.  
Amniotic fluid cell culture failure occurs in 0.1% of samples (ACOG, 2007b).   
While CVS and amniocentesis are most often used for chromosomal analysis by 
karyotyping, they can serve other functions.  CVS may be used to test for biochemical 
abnormalities, single gene conditions, and collagen abnormalities, but cannot test for 
open neural tube defects (ONTDs).  Amniocentesis can test for ONTDs, biochemical 
abnormalities, and single gene conditions (Wilson et al., 2012).    
1.2 Prenatal Screening Procedures 
Prenatal screening for aneuploidy is a standard of healthcare offered to all 
pregnant women.  Screening procedures allow high-risk pregnancies to be identified; 
women with these pregnancies are then offered diagnostic testing.  Two of the most 
common prenatal screening techniques are first trimester screening (FTS) and second 
trimester multiple marker screening (MMS).  Screening tools are meant to be highly 
accessible and do not present risk to the pregnancy.  Most laboratories target a 5% false 
positive rate for serum screening options (ACOG, 2007a). 
First trimester screening identifies trisomy 21 with a sensitivity of 90% and 
trisomies 18 and 13 with a sensitivity of 95% (ACOG, 2007a).  Nuchal translucency (NT) 
measurements are combined with maternal age and the levels of two proteins, human 
chorionic gonadotropin (hCG) and pregnancy plasma associated protein A (PAPP-A), to 
estimate the chance for aneuploidy unique to a pregnancy. PAPP-A and hCG are 
measured between 9w0d-13w6d, while the nuchal translucency (NT) measurement must 
be taken between 10w4d-13w6d.  The patterns of the levels of the serum analytes change 
the chance for aneuploidy.  For example, relative low hCG and low PAPP-A levels 
increases the chance for trisomy 18 or 13.  Likewise relative increased hCG and low 
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PAPP-A increases the chance for trisomy 21 (Shamshirsaz, Benn, & Egan, 2010).  A 
significantly elevated NT measurement (>3.0mm or the 95
th
 percentile) is correlated with 
an increased chance of chromosomal aneuploidy, and it is appropriate to offer diagnostic 
testing whether the patient has a positive screening result or not.  Elevated NT 
measurements above 3.5mm are associated with an increased chance of congenital heart 
defects; thus a fetal echocardiogram is appropriate.  A late development or lack of a 
lymphatic system could also cause an elevated NT measurement.  Even if a normal fetal 
karyotype is confirmed, the chance for an adverse pregnancy outcome remains elevated 
(ACOG, 2007a).   
One recent study summarizing the results of first trimester screening performed at 
a single clinical center over a 10-year period found first trimester screening to be 
efficacious in identifying pregnancies with trisomies 13, 18, and 21.  However, 29% of 
chromosomally abnormal fetuses identified to be at risk for these aneuploidies actually 
had a different chromosome complement.  The authors suggest that prior to invasive 
diagnostic testing following a positive serum screen, patients should be counseled about 
the possible presence of a fetal aneuploidy other than trisomies 13, 18, and 21 (Alamillo, 
Krantz, Evans, Fiddler, & Pergament, 2013). 
First trimester screening does not assess risk for ONTDs.  Thus, a maternal serum 
alpha-fetoprotein (MSAFP) screen should be offered in the second trimester to patients 
who choose to undergo FTS (ACOG, 2007a).   
There are three options for first trimester screening:  (1) NT only with maternal 
age uses only the fetal NT measurement and maternal age, (2) First trimester analyte 
screening uses the levels of the analytes combined with maternal age, and (3) Combined 
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first trimester screening uses the NT measurement, the serum analytes, and maternal age. 
The last approach has been shown to have the highest detection rates (ACOG, 2007a).   
Multiple marker screening is offered between weeks 15w0d-21w6d of gestation.    
This test assesses risk of trisomies 18 and 21 (not 13) and ONTDs by considering 
maternal age, weight, race, diabetic status, and protein analytes produced by pregnancy 
and found in the maternal bloodstream.  Options include the “triple” screen and the 
“quad” screen.  The triple screen measures the levels of maternal serum alpha-fetoprotein 
(AFP), hCG, and unconjugated estriol (uE3).  The quad screen adds dimeric inhibin-A 
(DIA), which increases the detection rate for Down syndrome.  The quad screen has a 
higher detection rate, with a sensitivity for Down syndrome of 75%-83% and a sensitivity 
for trisomy 18 of 60%-70% (ACOG, 2007a).   
Similar to FTS, MMS identifies patterns that indicate an increased chance for 
trisomies 18 or 21.  For example:  elevated hCG and DIA in association with low AFP 
and uE3 indicate increased risk for trisomy 21; and low AFP, hCG, and uE3 levels 
indicate increased risk for trisomy 18.  In addition, high levels of AFP (>2.5MoM) are an 
indication for an increased risk for an ONTD (Shamshirsaz et al., 2010).  
Typically, patients opt for FTS aneuploidy screening or second trimester MMS, 
depending at what gestational age they present for prenatal care; however some practices 
utilize a combined approach.  There are three options when combining FTS and MMS:  
integrated screening, stepwise sequential screening, and contingency screening.  Using a 
combined approach increases detection rates and decreases false positive rates, but poses 
the difficulty of requiring multiple appointments to complete the process.  All combined 
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screening approaches have similar detection rates. For example, integrated screening 
detects Down syndrome at 94%-96% and trisomy 18 at 91%-96% (Wilson et al., 2012).   
Integrated screening combines the results from NT and PAPP-A measurements in 
the first trimester and serum analytes AFP, hCG, uE3, and DIA in the second trimester.  
No results are revealed until after the second step, when they are combined.   Stepwise 
sequential screening begins with a first trimester calculation including an NT 
measurement, maternal age, and serum analytes PAPP-A and hCG.  Results are disclosed 
to individuals at high risk for fetal aneuploidy, and these individuals are offered 
diagnostic testing.  Individuals not in the high-risk group proceed to the second trimester 
blood draw, which uses serum analytes AFP, hCG, uE3, and DIA.  Contingency 
screening adjusts maternal age-alone chance for aneuploidy based on serum analytes and 
fetal NT measurement.  Patients are divided into low, medium, and high risk groups 
based on their results and are offered no further testing, the second trimester serum 
analyte screening step, or diagnostic testing, respectively.  The medium risk group are 
then further sorted into a high risk group who are offered diagnostic testing and a low risk 
group who are not offered further testing by the results of the second screening step 
(ACOG, 2007a).   
1.3 Noninvasive Prenatal Testing 
As early as 1997, Lo et al. recognized that cell-free fetal DNA (cffDNA) accounts 
for 5%-10% of total free-floating DNA in the maternal bloodstream and is easier to 
isolate from maternal blood than cellular fetal DNA (Lo et al., 1997).  This discovery 
prompted an effort to discover a reliable method for NIPT for fetal genetic conditions.  
Massively parallel sequencing (MPS) and selective analysis of cell-free fetal DNA in 
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maternal plasma are two methods that are highly sensitive and specific screening tools for 
common fetal chromosome aneuploidies (Wilson et al., 2012).   
MPS allows large quantities of cffDNA to be read in a short amount of time with 
high through-put sequencing.  Maternal and fetal DNA sequences are then assigned to the 
chromosome from which they originated and are quantified as a ratio.  This results in a 
specific amount of genetic material read for a particular chromosome, which can be 
compared to the amount of genetic material that is present if the genotype is typical.  An 
increase in detection of genetic material for chromosome 21, for example, would indicate 
trisomy 21 (Lo, 2012).   
Massively parallel sequencing has been instrumental in detecting subtle 
quantitative differences between affected and unaffected pregnancies.  Consider the 
example of detecting a pregnancy affected with trisomy 21:  if 5% of cell free DNA in 
the maternal bloodstream originates in the fetus, the cffDNA from each copy of 
chromosome 21 of an unaffected fetus comprises 2.5% of the total cell free DNA for 
chromosome 21 in the maternal bloodstream. A pregnancy affected with trisomy 21 
should have 2.5% more fetal chromosome 21 transcripts than an unaffected pregnancy. 
Because the mother supplies the majority (95%) of the cell free DNA, detecting a subtle 
2.5% overall difference requires advanced technology and laboratory expertise (Simpson, 
Richards, Ontano, & Driscoll, 2012).  
Identification of trisomies in twin gestations relies on a small incremental increase 
in the proportion of DNA fragments.  Both monozygotic and dizygotic twin pregnancies 
have higher placental mass than singleton pregnancies; thus it is expected they contribute 
more fetal DNA to maternal circulation and consequently have higher fetal fraction.   
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Canick et al. (2012) found that on average multiple pregnancies contributed 35% more 
fetal DNA to the total free DNA in maternal plasma than singleton pregnancies.  The 
largest study on MPS in twin gestations to date correctly classified seven pregnancies 
with trisomy 21, one with trisomy 13, and seventeen euploid pregnancies (two of which 
were triplets) with a detection rate of 100% and confidence interval of 95% (Canick et 
al., 2012).  However, if NIPT is abnormal, which twin is affected is indiscernible.  
Confirmation by amniocentesis of each fetal sac is recommended when fetal trisomy is 
detected in twin pregnancies by NIPT (Canick et al., 2012). 
Selective analysis sequences cell-free DNA from maternal plasma for selected 
loci from specific chromosomes of interest.  Selective analysis and MPS both utilize 
sequencing technology, but unlike MPS, selective analysis only sequences DNA from 
chromosomes of interest and not the entire genome, which increases throughput.  A novel 
selective analysis assay, digital analysis of selected regions (DANSR), generates 
sequencing templates from chromosome-specific assays and produces high mapping rates 
(Sparks et al., 2012).  Thus, selective analysis has been proposed to be a more efficient 
and less expensive option for NIPT.  Fetal-fraction optimized risk of trisomy evaluation 
(FORTE), a process of using fetal fraction of cffDNA results from sequencing cffDNA 
and generating a risk score, has been shown to estimate accurately the risk of aneuploidy 
(Sparks et al., 2012).    
At least 5% of NIPT samples are yielding noninformative results due to 
insufficient cffDNA.  Samples can be taken at 10 weeks gestation or any time after, but 
cffDNA levels do not increase with advancing gestational age (Simpson, 2013).   
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The newest advancements in NIPT focus on attaining diagnostic competency for 
aneuploidy detection, but this technology also provides access to RhD genotyping, fetal 
sex determination, paternity testing, and limited single gene testing.  Although the 
proposed research project focuses on advancements in detecting fetal chromosomal 
aneuploidy, it should be recognized that NIPT has been used to fulfill these other 
purposes, which will be described briefly.  Detection of RhD sequence in the bloodstream 
of an RhD-negative mother indicates the fetus is RhD-positive and warrants 
administration of Rh immune globulin.  Using the same strategy, if Y-sequence is 
detected in the maternal bloodstream, one may deduce that the fetus is generating this 
genetic material and thus is a male (Simpson et al., 2012).  Paternity is determined using 
informative single nucleotide polymorphisms (SNPs) (ie. occurring when the mother and 
one potential father are homozygous for the same allele while the other potential father is 
homozygous for the alternative allele) (Guo et al., 2012). Certain Mendelian disorders 
can be detected from cffDNA if they are paternally derived.  For example, polycystic 
kidney disease, inherited as an autosomal dominant trait, may be detected in the fetus 
noninvasively if the presence of the paternal mutation is found in the blood of the 
unaffected mother (Simpson et al., 2012). 
NIPT as a prenatal testing option is rapidly evolving yet has limitations.  
Conjecture has been put forth that NIPT will eventually reach diagnostic standards 
similar to CVS but not amniocentesis.  This expectation recognizes that cffDNA are 
derived from trophoblasts, the same tissue studied in CVS.  Other complications that can 
occur with CVS may potentially occur with NIPT as well, such as placental mosaicism.  
NIPT will not distinguish between trisomy and unbalanced translocation because the test 
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measures the quantity of each chromosome present in the fetus and does not provide a 
karyotype image (Benn, Cuckle, & Pergament, 2012).  Despite current limitations, the 
technology supporting NIPT continues to advance and will likely have a considerable 
role in current and future prenatal assessment algorithms. 
1.4 Noninvasive Prenatal Testing: Transitioning from Laboratory to Clinical 
Practice 
The development of NIPT has been funded primarily by the private sector and is 
considered a Laboratory Developed Test (LDT).  LDTs are developed, evaluated, and 
validated within one laboratory; unlike commercial tests, they are not manufactured and 
marketed to several labs.  Consequently, LDTs are not regulated by the U.S. Food and 
Drug Administration. Multiple laboratories have developed processes for NIPT (Orton, 
2012). 
Three large-scale clinical trials have been published by two separate groups that 
used MPS of maternal plasma to detect an overrepresentation of chromosome material.  
An international study using MPS released two sets of analyzed data: one on trisomy 21 
in 2011 and one on trisomies 18 and 13 in 2012.  This multicenter study detected trisomy 
21 with a sensitivity and specificity close to 99% (Palomaki et al., 2011).  The follow-up 
study detected trisomy 18 with a sensitivity of 100% and a specificity of 99.7% and 
trisomy 13 with a sensitivity of 91.7% and a specificity of 99.1% (Palomaki et al., 2012).   
Another group also used MPS to evaluate high-risk pregnancies for chromosome 
conditions.  This study detected trisomy 21 with a sensitivity of 100%, trisomy 18 with a 
sensitivity of 97.2%, and trisomy 13 with a sensitivity of 78.6%.  All three were detected 
with a specificity of 100%.   In addition, this study found a 94% detection rate for 
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monosomy X and reported several cases of mosaicism for trisomy 21, trisomy 18 and 
monosomy X (Bianchi et al., 2012).  
Other studies have validated NIPT through selective analysis.  A multicenter 
cohort study performed chromosome-selective sequencing on chromosomes 21 and 18 in 
a population of women undergoing CVS or amniocentesis for any indication.  The 
sensitivity and specificity for trisomy 21 were 100% and 99.97%.  The sensitivity and 
specificity for trisomy 18 were 97.4% and 99.93% (Norton et al., 2012).  Another study 
reported 80% sensitivity and 99.95% specificity for trisomy 13 (Ashoor, Syngelaki, 
Poon, Rezende, & Nicolaides, 2013). 
NIPT first became clinically available in October of 2011 when Sequenom 
released MaterniT21™, a test for Down syndrome that uses MPS to detect cffDNA 
(Sequenom CMM, 2011).  Sequenom has since included detection for chromosomes 13, 
18, and Y in the more recent version of its test, MaterniT21Plus™ (Palomaki et al., 
2011).  In 2012, Sequenom provided evidence that MPS could reliably detect Down 
syndrome in women with high-risk twin gestations and added this testing option (Canick 
et al., 2012).  In February, 2013, Sequenom’s MaterniT21Plus™ included detection for 
sex chromosomal aneuploidies (PR Newswire, 2013).   
LabCorp (Ariosa Diagnostics) and Verinata Health released similar tests in 2012, 
Harmony™ and verify™, respectively.  Harmony™ uses MPS to detect cffDNA for 
chromosomes 21, 18, and 13.  Verifi™ uses MPS to detect chromosomes 21, 18, 13, X, 
and Y; thus sex chromosomal aneuploidies such as monosomy X, XXX, XXY, and XYY 
are reported (PR Newswire, 2012a; PR Newswire 2012b). Natera is undergoing a clinical 
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trial, PreNATUS, and once clinically validated will offer testing for trisomies 21, 13, and 
18 and sex chromosomal aneuploidies (Biotechnology Industry Organization, 2012).   
The clinical function of NIPT has been debated.  The high sensitivity of the test 
has called to question whether it may be used for diagnostic purposes.  In fact, NIPT is 
also known in current literature as noninvasive prenatal diagnosis (NIPD).  However, 
guidelines and statements issued by professional organizations agree that NIPT should be 
considered a screening tool at this point in time, and only offered to high risk 
populations.  A 2012 position statement by the National Society of Genetic Counselors 
(NSGC) stated that currently it “is recommended only as a highly specific screening 
measure for high-risk pregnancies, which requires follow-up diagnostic testing” (Devers 
et al., 2013).  The International Society for Prenatal Diagnosis (ISPD) made a similar 
statement, which follows: “[T]his test is not fully diagnostic and therefore constitutes an 
advanced screening test.  Accordingly, confirmation of MPS positive results through 
invasive testing would still be required” (Benn et al., 2011b, p.1).  The American College 
of Obstetricians and Gynecologists (2012) reaffirmed this position in their committee 
opinion, stating, “A patient with a positive test result should be referred for genetic 
counseling and should be offered invasive prenatal diagnosis for confirmation of test 
results” (ACOG, 2012, p.1).  
The NIPT clinical validation studies recruited only women who were otherwise 
pursuing invasive testing; thus the majority of pregnancies were high-risk for aneuploidy.  
Consequently, testing is currently offered to high-risk populations only.  Current 
indications for NIPT include:  advanced maternal age, an abnormal maternal serum 
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screen, personal or family history of aneuploidy, or an abnormal ultrasound (Wilson et 
al., 2012).  
Clinical validation studies of the general population (i.e., low-risk patients) are in 
process.  Preliminary evidence indicates NIPT should have similar sensitivity and 
specificity in a low-risk population (Nicolaides, Syngelaki, Ashoor, Birdir, & Touzet, 
2012).  Indeed, research has suggested that NIPT may be an effective screening method 
as a standard test for risk assessment of fetal trisomies 21, 18, and 13 in the general 
population (Fairbrother, Johnson, Musci, & Song, 2013). With further support, this 
advanced prenatal test may be offered to women with low-risk pregnancies (Norton et al., 
2012).   
1.5 Patients’ Decision-making in Prenatal Testing 
The number of prenatal testing options available to prospective parents has 
significantly increased during the past half-century.  This presents prenatal patients with 
what can feel like a menu of confusing choices.  The methods used to navigate these 
choices and reasons for making decisions are unique to each woman, and healthcare 
providers should be aware of the surrounding complexities in order to provide standard 
care (Pergament & Pergament, 2012).     
Screening options are noninvasive, which make them attractive for patients who 
desire individualized risk assessment information about their pregnancy but do not want 
an associated risk of miscarriage, or for those who would like to use screening results to 
make a decision about whether or not to undergo more comprehensive diagnostic testing.  
The primary limitation of screening is that it does not provide a definitive diagnosis, 
potentially creating anxiety in women with unaffected pregnancies and falsely reassuring 
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women with affected pregnancies (ACOG, 2007b).  Diagnostic tests offer a definitive 
result, but are associated with a risk of miscarriage (Collins & Impey, 2012).   
Many women find NIPT appealing because it gains near-diagnostic genetic 
information about the fetus without an associated chance of miscarriage.  In fact, when 
assessing pregnant women’s level of future interest in NIPT, one study found pregnant 
women thought the most important feature of NIPT would be the safety of the fetus 
(75%), followed by accuracy (13%), and early availability of results (7%) (Tischler, 
Hudgins, Blumenfeld, Greely, & Ormond, 2011).   
Reproductive decisions must be understood within the cultural context of the time 
period, as genetic testing is constantly evolving.  Today in the United States, a strong 
emphasis is placed on personal choice, and individuals have unlimited access to 
information and external influences, such as the media, the internet, and social media 
(Pergament & Pergament, 2012).  The uptake of prenatal testing has increased, which 
reflects the growing need in couples to seek further information genetic about their fetus 
(Pivetti, Montali, & Simonetti, 2012).  Prospective parents have higher expectations than 
in the past of a successful reproductive outcome (Choolani & Biswas, 2012).  This 
expectation could potentially stimulate a desire for reassurance about the pregnancy 
through prenatal testing.   
There are a multitude of personal and social factors that directly and indirectly 
affect women’s prenatal testing decisions.  In general, it is accepted that “decision-
making by prospective parents is based on rational assessment of risk, benefit, and 
choices, specifically: (1) the risk of a fetal abnormality compared with the loss of a 
normal pregnancy after invasive testing; (2) the benefit of gaining reassurance of a 
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healthy fetus; and (3) the options available if the fetus is identified as affected by a 
genetic, developmental disorder, or both” (Pergament & Pergament, 2012, p. 518).  
While these are useful guidelines, understanding specifically what is important to a 
patient has important implications in the delivery of service.   
Factors that influence women’s reproductive decisions following genetic 
counseling may include, for example: perceived pain of diagnostic testing, perceived risk 
of diagnostic testing, anxiety of health about the fetus, emotional and social burden of 
possible pregnancy termination, financial and social burden of a child with disabilities, 
access to prenatal services, past pregnancy history, socioeconomic status, personal 
philosophy, social and partner support, healthcare education and support, media, and 
uncertainty of genetic tests.  Of course, the importance of each factor, how it interacts 
with other factors, and the influence it might have over a particular woman’s decision 
varies.  It is difficult to measure objectively the role each factor plays in a decision 
(Pergament & Pergament, 2012). 
The overall most frequently reported sources of difficulty for decision-making in 
women in a systematic review of 32 unique studies regarding perceptions of Down 
syndrome prenatal testing were pressure from others, emotions, and lack of information.  
The same study found the most important sources of reassurance for women to be 
personal values, understanding, and confidence in the medical system (St-Jacques et al., 
2008). 
Prenatal patients often feel ambivalence towards screening and diagnosis of 
aneuploidy (Vassy, 2005).  It has been postulated that for many women the miscarriage 
risk associated with invasive testing is a psychological barrier to diagnostic testing and 
16 
 
that if this risk were removed, women may feel more inclined to have a diagnostic test 
(Newson, 2008).  Noninvasive prenatal testing may present an option for near-diagnostic 
information about fetal aneuploidy without an associated risk of miscarriage for these 
women. 
However, some women prefer not to have genetic knowledge of their fetus if the 
knowledge does not alter their course of action.  Because it is not possible to correct a 
chromosome condition cytogenetically, many women perceive termination as the only 
available option in light of a positive testing result.  A meta-analysis of pregnant 
women’s decision making processes with regard to prenatal screening for Down 
syndrome showed that some women consider genetic testing to be pointless, since they 
would not terminate the pregnancy even if the result were positive (Reid, Sinclair, Barr, 
Dobbs, & Crealey, 2009). 
Other women consider genetic testing to be empowering, even if they would 
choose not to terminate an affected pregnancy.  In fact, one study concluded that the 
introduction of NIPT is likely to cause a shift in decision-making that may be associated 
with an increase in the uptake of prenatal testing but a decrease in the decision to 
terminate pregnancies affected with Down syndrome (Verweij, Oepkes, & De Boer, 
2013).  Another study surveyed parents of children with Down syndrome:  75% were 
disinclined to terminate a future affected pregnancy, but only 33% would not have 
prenatal testing (Kuppermann et al., 2011).  Learning of a fetus’ diagnosis may provide 
the patient time to share the diagnosis with a support network and prepare emotionally. 
Studies have been performed to evaluate uptake of invasive diagnostic testing 
following unexpected results.  Women are more likely to undergo invasive diagnostic 
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testing when fetal anomalies are detected on ultrasound or a screening test result is 
positive, due to the increased chance for chromosomal aneuploidy (Pryde, Drugan, 
Johnson, Isada, & Evans, 1993).  A more recent study evaluating factors determining 
uptake of invasive testing following first-trimester combined testing found that women 
opting for invasive testing are significantly younger and less likely to have had IVF/ICSI.  
Women less than 36 years old opt for invasive testing more frequently, regardless of their 
chance for Down syndrome, while women 36 years or older are more likely to let the 
magnitude of the chance estimate guide their decision (Lichtenbelt et al., 2013).   
Research examining psychosocial determinants that influence women’s intention 
to undergo prenatal genetic testing found women are more inclined to feel favorably 
about prenatal genetic testing if they: (1) are in favor of science and scientific 
progression, (2) possess a good knowledge of genetic testing, and (3) can count on the 
support of family members and friends. Women’s attitudes about pregnancy termination 
are the most predictive indicators of intent to undergo prenatal testing (Pivetti et al., 
2012).   
Experience in previous pregnancies has been shown to play a role in women’s 
prenatal testing decisions.  Research demonstrates that women who had a previous 
miscarriage or termination are more likely to undergo testing than women who have 
already given birth to three or more children (Halliday, Lumley, & Watson, 1995).   
Research has indicated that women’s perceptions of chance of miscarriage or of 
having an affected fetus may form independent of empirical risk estimates.  For example, 
women aged 35 years and older have a higher perceived chance of Down syndrome than 
younger women (this chance is higher in women 35 and over) but a lower perceived 
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chance of a procedure-related miscarriage (this chance is the same for both parties).  
Other correlations were made between race, socioeconomic status, education level, and 
perception of health.  Interestingly, women who undergo diagnostic testing perceive a 
higher chance of having a baby with Down syndrome and a lower chance of a procedure-
related miscarriage than women who choose not to have a diagnostic procedure 
(Caughey, Washington, & Kuppermann, 2008).   
Some women are apprehensive about expected pain related to a procedure 
(Mujezinovic & Alfirevic, 2011).  Research from Turkey reported that actual pain after 
amniocentesis was significantly lower compared with perceived pain before the 
procedure and anxiety before amniocentesis was significantly higher than anxiety after 
the procedure. Of particular interest, women who were informed about the procedure 
beforehand perceived the procedure to be less painful and expressed less anxiety before 
and after amniocentesis.  The authors suggested that pre-amniocentesis counseling should 
emphasize that the actual pain and anxiety experienced during amniocentesis are often 
significantly lower than expected (Al, Yalvac, Altar, & Dolen, 2009).   
 Patients’ own demographic characteristics play roles in their prenatal testing 
decision making.  A meta-analysis of three national polls over a 14-year period, from 
1990 to 2004 found married/separated/widowed individuals and those who attended 
church on a regular basis were less likely to want prenatal testing than individuals who 
were single and/or attended church less often.  Catholics were significantly less likely, 
and Jewish individuals significantly more likely to opt for prenatal genetic testing 
(Singer, Couper, Raghunathan, Van Hoewyk, & Antonucci, 2008).  Another study 
documented ethnic differences in the decision to undergo or not undergo prenatal 
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screening for aneuploidy, with women from minority groups and of non-Western ethnic 
origin less likely to participate (Fransen et al., 2010). 
The attitudes of health professionals have been shown to impact the uptake of 
Down syndrome screening.  In fact, in a study assessing pregnant women’s interest in 
NIPT, one in five women said that they would do what their health professional 
recommended (Tischler et al., 2011).   
Trends have been observed in differences between what women and healthcare 
providers consider most important when making a decision about prenatal testing.  
Choolani & Biswas (2012) point out that when it comes to risk and benefit of prenatal 
testing, what healthcare professionals feel is important, what patients feel is important, 
and what healthcare professionals believe patients feel to be important are often three 
completely separate things.   Health professionals tend to place a higher value on tests 
that are conducted earlier in pregnancy than women, who prefer to wait for a result until 
later in pregnancy if the test is safer and more accurate.  This discrepancy potentially 
could result in screening policies that overemphasize timing in the selection of a test to 
the relative neglect of tests associated with lower miscarriage rates and higher detection 
rates but conducted later in pregnancy (Bishop et al., 2004).   
In another study, both women and health professionals preferred a test with 
greater accuracy, no risk of miscarriage, and one that provided as much information as 
possible.  However, opinions between the two groups had statistically significant 
differences in the coefficients for accuracy, timing, and no risk of miscarriage.  Women 
strongly preferred a test with no risk of miscarriage:  they were prepared to wait more 
than twice as long and accept 12% lower accuracy for a test that had no risk of 
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miscarriage as compared with health professionals.  In contrast, health professionals 
preferred to offer a more accurate test, even if it was associated with a small risk of 
miscarriage (Hill, Fisher, Chitty, & Morris, 2012). 
Further subgroup comparisons in this discrete choice experiment indicated that 
women aged 35 years or more placed a greater emphasis on accuracy than younger 
women.  Women who had undergone Down syndrome screening in their current 
pregnancy differed from those who had declined Down syndrome screening in the 
emphasis they placed on test timing and information.  Of the 50 women who chose not to 
have screening for Down syndrome, only 12 indicated that they would not have any test 
presented to them on the questionnaire.  The authors suggested many of the women who 
declined screening for Down syndrome may choose to undergo testing if there is no risk 
of miscarriage associated with the definitive diagnosis (Hill et al., 2012).   
1.6 Clinical and Ethical Implications of Noninvasive Prenatal Testing 
The extraordinary momentum with which the technology of NIPT has forged 
ahead is impressive.  However, many feel hesitant to offer NIPT in a clinical setting 
without further consideration of ethical repercussions.  It is the responsibility of those 
who provide and regulate healthcare to reflect on the benefits and risks of particular tests 
so that these are explained to patients, guidelines are established, and advancements in 
NIPT progress in a responsible manner.   
NIPT presents many advantages to women.  It is a noninvasive test without 
association of miscarriage that supplies highly sensitive results and imposes less time 
restrictions on gestational age than other prenatal tests.  Eliminating the risk of 
miscarriage associated with invasive testing means women do not have to factor this 
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anxiety-producing prospect into their decision.  Early detection of unaffected pregnancies 
could allow for parental reassurance and for bonding to occur sooner (Newson, 2008). 
Women with affected pregnancies have advantages in their options as well.  Parents may 
use this time to prepare emotionally, make an appropriate delivery plan, and assemble a 
medical management team.  If parents decide to terminate an affected pregnancy, this 
may be physically safer and psychologically less traumatic at an earlier gestational age 
(Benn & Chapman, 2010).   
For some, the fact that a termination can occur early in gestation may make a 
morally relevant difference.  De Jong et al. (2010) point out that the dominant opinion in 
most western countries, also reflected in legislation, is that the moral status of the fetus 
progressively increases with its development (De Jong, Dondorp, De Die-Smulders, 
Frints, & De Wert, 2010). Current guidelines recommend abnormal NIPT results be 
confirmed by CVS or amniocentesis prior to termination, so there may be additional 
delay after the results of the NIPT are received before the diagnosis is confirmed.  This 
could present a stressful period of waiting. (Benn et al., 2012).   
Some have expressed concern about potential negative repercussions of NIPT 
because there is no increased risk for miscarriage.  The uptake of NIPT has been 
projected to increase detection of affected pregnancies and may in turn lead to an 
increased number of terminations (Newson, 2008).  When understood from this 
perspective, the ease with which this test is undertaken and the fact that results are 
received early in pregnancy are seen by some as threatening conveniences that may 
promote termination of affected pregnancies.  It has been suggested that receiving results 
of an affected fetus at an early gestational age, perhaps before parents have bonded with 
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the fetus or shared publicly the pregnancy encourages termination without thoughtful 
reflection  (Skotko, 2009).   
This concern has been further projected: NIPT may lead to fewer individuals with 
disabilities to be born, which may lead to reduced social acceptance and financial support 
for those who live with disabilities (Skotko, 2009).  Some disability advocates contend 
that the implicit aim of prenatal genetic testing is to prevent the birth of disabled babies, 
which demeans and undermines the worth of individuals living with disabilities (Benn & 
Chapman, 2010).  If this apprehension becomes reality, it has been suggested that societal 
pressures regarding individuals with disabilities may cause women to feel undue pressure 
to undergo NIPT and terminate an affected pregnancy (Tischler et al., 2011).   
Advocates of the disability community are not alone in their concern about the 
potential negative effects of NIPT on the reproductive trends of the population. Many 
worry there could be unintended consequences.  One such concern is that the risk-free 
and simple process of NIPT will lead to the routinization of the test.  In other words, 
NIPT may become a standard test that most women uptake simply because other women 
uptake and thus it seems “normal”.  While this might increase efficiency and improve 
uptake, routinization could potentially undermine the decision-making process (Deans & 
Newson, 2011).  Others feel alarmed by the reproductive power NIPT offers and wonder 
if in the future, a fetus might have to meet certain standards of desirable traits to qualify 
for birth.  One ethicist suggested that potentially “every pregnancy becomes a ‘tentative 
pregnancy’ pending the results of prenatal screening” (Benn & Chapman, 2010, p. 131).  
A primary cause for unease in this ethical quandary revolves around the concern 
that patients may not be afforded equal quality of pretest counseling as they would with 
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an amniocentesis or CVS.  Obviously, women do not need to be counseled about risk of 
miscarriage associated with NIPT.  To some extent, this lessens the gravity of the 
decision of prenatal testing, and indicates a difference in counseling between NIPT and 
invasive testing.  However, the definitive nature of the information received and the 
significance of the decisions that might be made from this information necessitates 
pretest genetic counseling (Deans & Newson, 2011).   
Because pretest informed consent is imperative for NIPT, there is an increased 
need for genetic counseling ( Benn, Cuckle, & Pergament, 2012).  The genetic counselor 
and the obstetrician serve to provide accurate and objective information about the 
implications, advantages, disadvantages, and consequences of any genetic testing 
(Pergament & Pergament, 2012).   Patients have indicated mixed interest in pretest NIPT 
counseling but seem eager to meet with a genetic counselor to discuss results.  A 2011 
study assessing women’s potential interests in NIPT demonstrated 50% of respondents 
indicated they would like pretest genetic counseling and 94.6% were interested in 
discussing test results with a genetic counselor (Tischler et al., 2011).    
NIPT has invoked a variety of attitudes and opinions in healthcare and among the 
public about how most responsibly and ethically to implement this new option.  Among 
attendees at a continuing medical education course on obstetrics and gynecology in 2011, 
enthusiasm, caution, discomfort, and uncertainty were among the feelings that 
surrounded the test.  Genetic counseling and professional society approval were rated 
important to the implementation of NIPT.  Respondents indicated a higher comfort level 
with the idea of offering testing for chromosomal abnormalities or single-gene disorders 
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than for sex determination or late-onset conditions (Sayres, Allyse, Norton, & Cho, 
2011).  
 A similar study assayed public opinion on NIPT.  The majority (63%) of 
respondents relayed a positive first impression of NIPT.  Yet many expressed 
ambivalence, affirming the individual/medical rationale for NIPT but expressing unease 
concerning the public health rationale and societal implications.  Subjects of concern 
included eugenic reasoning, too much reproductive control, commercial provision, 
information and support requirements for expanded testing, and limiting the use of 
testing.  These results suggest that public preference is to regulate commercial provision 
of NIPT services and to monitor its introduction and clinical use (Kelly, 2012). 
 Noninvasive prenatal testing presents patients, genetic counselors, and physicians 
with exciting opportunities to gain accurate knowledge of a fetus early in gestation 
without increasing the risk of miscarriage.  As this technology is integrated into prenatal 
practice, quality informed consent is imperative as well as thoughtful consideration of 
how best ethically and responsibly to employ NIPT.  Despite the conflict surrounding 
NIPT, its presence in the prenatal setting is powerful and undeniable; it has major 
implications on reproductive health important to all (Tischler et al., 2011).  It is essential 
that healthcare providers appreciate how NIPT changes the realm of prenatal testing from 
the perspective of a patient and complicates the decision-making process.   
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Prenatal Decision-making Process of Patients in Three Cities in South Carolina
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2.1 Abstract 
Purpose: Noninvasive prenatal testing (NIPT) has changed the landscape of prenatal 
testing.  This novel test, which can be performed as early as 10 weeks gestation without 
risk of pregnancy complication, has evoked questions about its applicability, appropriate 
use, and patient response.  The purpose of this study was to evaluate patient decision-
making processes about prenatal testing options as NIPT is integrated into the clinical 
realm.  Method: Prenatal patients who were offered NIPT during genetic counseling (N = 
105) in three cities in South Carolina completed a survey to address the goals of this 
study. Results: The top five factors most frequently rated as important to their decision-
making about prenatal testing by participants were as follows:  (1) To be prepared if the 
baby had a disability (91%), (2) To avoid the risk of miscarriage (88%), (3) For 
reassurance the baby does not have a genetic condition (86%), (4) To obtain genetic 
information about the fetus as early as possible (81%), and (5) To have a test that 
provides more accurate information than other tests (77%).  Three factors were found to 
be significantly more important to participants who selected NIPT than to participants 
who did not:  (1) To obtain genetic information about the fetus as early as possible (p = 
.021), (2) To have a test that provides more accurate information than other tests (p = 
.025), and (3) To be prepared if the baby had a disability (p = .001).  In addition, a 
majority of participants (74%) felt consideration of termination if the baby had a 
chromosome condition was irrelevant to their decision.  This factor was not an NIPT-
selection factor, meaning participants who selected NIPT were not significantly more 
likely to find this factor important to their decision than participants who did not select 
NIPT.  Conclusions: Patients are faced with new decisions as NIPT is integrated into 
prenatal testing options.  This study evaluated the top five factors most frequently rated 
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as important by participants about their prenatal testing decision and identified three 
NIPT-selection factors.  While every patient should be counseled as a unique individual, 
the results from this study are observations that may help healthcare providers better 
understand patient perspective This study reveals five factors important to patient 
decision-making regarding prenatal testing; of these, three factors (obtaining genetic 
information about the fetus as early as possible, having a test that provides more accurate 
information than other tests, and being prepared if the baby had a disability) were 
significantly influential in patient selection of NIPT.   
 Keywords:  Noninvasive prenatal testing (NIPT), patient decision making, 
decision-making process, prenatal genetic testing 
2.2 Introduction 
Since 2011, noninvasive prenatal testing (NIPT) has been clinically available to 
obtain near-diagnostic results for aneuploidy as early as 10 weeks gestation without risk 
of pregnancy complication (Wilson et al., 2012).  As this novel test integrates into the 
prenatal clinic, questions have been raised about its applicability, appropriate use, and 
how patients will respond.   
Prenatal testing has traditionally been divided into screening and diagnostic tests.  
Prenatal screening for aneuploidy is a standard of healthcare offered to all pregnant 
women.  Screening procedures allow high-risk pregnancies to be identified; women with 
these pregnancies are then offered diagnostic testing.  Screening tools are meant to be 
highly accessible and do not present risk to the pregnancy (ACOG, 2007a).  Conversely, 
prenatal diagnosis is typically offered by healthcare practitioners to patients whose 
pregnancies are at increased risk for chromosomal abnormalities or genetic disorders.  
These invasive methods provide sensitive results about genetic conditions but are 
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associated with procedure-related complications, such as a risk of miscarriage (Collins & 
Impey, 2012).   
Noninvasive prenatal testing uses cell-free fetal DNA (cffDNA) from the 
maternal bloodstream to achieve near-diagnostic results for aneuploidy without an 
associated risk of miscarriage.  Noninvasive prenatal testing is currently not available to 
all patient populations.  The NIPT clinical validation studies recruited only women 
otherwise pursuing invasive testing; thus the majority of pregnancies were high-risk for 
aneuploidy.  Consequently, testing is currently offered to high-risk populations only.  
Current indications for NIPT include:  advanced maternal age, an abnormal maternal 
serum screen, personal or family history of aneuploidy, or an abnormal ultrasound 
(Wilson et al., 2012).  Clinical validation studies of the general population (i.e., low-risk 
patients) are in process and may become a reality in the near future   (Nicolaides, 
Syngelaki, Ashoor, Birdir, & Touzet, 2012; Fairbrother, Johnson, Musci, & Song, 2013; 
Norton et al., 2012).   
Prenatal patients often feel ambivalence towards screening and diagnosis of 
aneuploidy (Vassy, 2005).  The primary limitation of screening is that it does not provide 
a definitive diagnosis, potentially creating anxiety in women with unaffected pregnancies 
and falsely reassuring some women with affected pregnancies (ACOG, 2007b).  
Diagnostic tests offer a definitive result, but are associated with a risk of miscarriage 
(Collins & Impey, 2012).  The high sensitivity of NIPT has called to question whether it 
may be used for diagnostic purposes.  However, guidelines and statements issued by 
professional organizations agree that NIPT should be considered a screening tool at this 
29 
 
point in time, and recommend that positive results be followed up by invasive diagnostic 
procedures (ACOG, 2012; Benn et al., 2011a;  Devers et al., 2013). 
There are a multitude of personal and social factors that directly and indirectly 
affect women’s prenatal testing decisions.  Many women find NIPT appealing because it 
gains near-diagnostic genetic information about the fetus without an associated chance of 
miscarriage.  In fact, when assessing pregnant women’s level of future interest in NIPT, 
one study found pregnant women thought the most important feature of NIPT would be 
the safety of the fetus (75%), followed by accuracy (13%), and early availability of 
results (7%) (Tischler, Hudgins, Blumenfeld, Greely, & Ormond, 2011).   
NIPT presents many advantages to women.  However, some have expressed 
concern about potential negative repercussions of NIPT because there is no increased risk 
for miscarriage.  The uptake of NIPT has been projected to increase detection of affected 
pregnancies and may in turn lead to an increased number of terminations (Newson, 
2008).  When understood from this perspective, the ease with which this test is 
undertaken and the fact that results are received early in pregnancy are seen by some as 
threatening conveniences that may promote termination of affected pregnancies (Skotko, 
2009).   
NIPT presents patients, genetic counselors, and physicians with exciting 
opportunities to gain accurate knowledge of a fetus early in gestation without increasing 
the risk of miscarriage.  As this technology is integrated into prenatal practice, quality 
informed consent is imperative as well as thoughtful consideration of how best ethically 
and responsibly to employ NIPT.  Despite the conflict surrounding NIPT, its presence in 
the prenatal setting is powerful and undeniable. It has major implications on reproductive 
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health important to all (Tischler et al., 2011).  Healthcare providers need to appreciate 
how NIPT shifts the realm of prenatal testing and understand how to evaluate opinion of 
this change.   
2.3 Materials and Methods 
2.3.1 Participants.  This study surveyed prenatal patients who were offered NIPT 
during genetic counseling about the motivations and reasons for their prenatal testing 
decision.  Regardless of their prenatal testing decision, eligible patients were invited to 
participate by genetic counselors after the genetic counseling session ended. Interested 
patients were given the option to complete a survey at the prenatal office or to mail a 
response in a pre-paid envelope.  For every patient who completed a survey, a genetic 
counselor completed a data collection form with basic information about the patient’s 
indication for genetic counseling, testing offered, and testing decision.  The patient 
surveys and genetic counselor data collection forms were numbered in sets such that data 
collection forms could be matched to respective patient surveys. Thus, patient 
confidentiality was maintained.  Three South Carolina locations were sampled:  
University Specialty Clinics of University of South Carolina School of Medicine in 
Columbia, Medical University of South Carolina in Charleston, and the Greenville 
Hospital System in Greenville.  This study was approved by the Institutional Review 
Board at the Medical University of South Carolina in December, 2012.   
 2.3.2 Research Methods.  The patient survey consisted of a series of questions 
designed to assess factors most influential to patients in their prenatal testing decision.  
The format of the survey was primarily quantitative and utilized both Likert scale and 
multiple choice questions with the opportunity to specify other possible responses.  The 
final question was open-ended and thus qualitative in nature.  In total, the survey 
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consisted of thirty items.  Questions were engineered to assess patient prenatal testing 
intentions pre- and post- genetic counseling.  Patients were asked to rank the importance 
or relevance of specific factors to their decision, such as insurance covering testing or a 
recommendation by a physician.  Demographic information was collected related to age, 
gestational age, annual household income, etc.      
The genetic counselor data collection form was engineered to provide objective 
and accurate patient information about indication for genetic counseling, gestational age, 
testing offered during genetic counseling, and testing currently pursued.  This form 
consisted of four quantitative questions, mostly multiple choice.   
2.3.3. Statistical Analysis.  Statistical Package for the Social Sciences (SPSS), 
version 21.0, was used to analyze quantitative data.  Ordinal categorical data were 
reviewed using frequency, proportions, and percentages.  Likert scale questions were 
reviewed item by item.  In addition, an exploratory factor analysis was performed and 
reliability statistics calculated to determine if items were similar enough to create a 
“factor”.  These items were reviewed as categorical groups.  Chi-square tests were used 
to compare responses of Likert scale questions.  Multiple response questions were coded 
individually by response and analyzed using Chi-square test and Fisher’s Exact Test.  
Open-ended responses were categorized into thematic groups and sub-groups for 
reporting. 
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2.4 Results   
Data were collected from December, 2012, to March, 2013.  A total of 105 patient 
surveys accompanied by genetic counselor data collection forms were collected:  51 from 
Columbia, SC, 32 from Charleston, SC, and 22 from Greenville, SC.  Patient surveys 
were fully completed by 104 participants.  Twenty-six genetic counselor data collection 
forms were received unaccompanied by patient surveys and thus were omitted from data 
analysis.    
Results reported as “important” include “very important” and “somewhat 
important” responses; similarly, results reported as “unimportant” include “very 
unimportant” and “somewhat unimportant”.  Some results are still reported as “very 
important” or “very unimportant”.  Non-statistically significant results can be found in 
Appendix C.   
 2.4.1. Sample Demographics.  All participants were female and pregnant.  The 
plurality of participants presented during their first trimester, was between the ages of 35 
and 39, possessed a high school/GED education, earned between $20,000 and $50,000, 
had private insurance, and received genetic counseling in Columbia, SC (Table 2.1).   
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Table 2.1 Personal Characteristics of Participants 
  
Personal 
Characteristics n % 
Location 
    Greenville 22 21% 
  Charleston 32 30% 
  Columbia 51 49% 
Estimated Household 
Income 
    Less than $20,000 31 31% 
  $20,000-$50,000 28 28% 
  $50,000-$80,000 12 12% 
  $80,000-$110,000 12 12% 
  Greater than $110,000 17 17% 
Highest Level of Education 
    Less than High School 1 1% 
  High School / GED 39 38% 
  Associate's Degree 19 18% 
  Bachelor's Degree 27 26% 
  Advanced Degree 18 17% 
Age at Due Date 
    15-19 3 3% 
  20-24 4 4% 
  25-29 13 13% 
  30-34 12 12% 
  35-39 56 54% 
  40-45 16 15% 
Pregnancy Trimester at Visit 
    First 58 56% 
  Second 45 43% 
  Third 1 1% 
Insurance 
    Medicaid 37 36% 
  Private 60 59% 
  Both 5 5% 
 
 2.4.2 Participant Indications and Prenatal Testing Offered and Selected. 
Participants were referred to genetic counseling for a variety of reasons, including 
advanced maternal age, a positive screening test, abnormal ultrasound findings, and a 
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family history of a genetic condition.  The most common indication was advanced 
maternal age (Figure 2.1).  This information was obtained from the genetic counselor 
data collection form.   
 
Figure 2.1 Participants’ Indications for Referral to Genetic Counseling 
 As being offered NIPT during prenatal genetic counseling was a requisite for 
participation in the study, 100% of participants were offered this test.    Other possible 
options included first trimester screening (FTS), chorionic villus sampling (CVS), 
multiple marker screening (MMS), amniocentesis, and other (notably, one center often 
wrote in “ultrasound only” for the other category).  Noninvasive prenatal testing was the 
test most offered to participants, with amniocentesis offered second most often.  Options 
for testing that were offered to participants are presented in Figure 2.2.  This information 
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was obtained from the genetic counselor data collection form.  
 
Figure 2.2 Procedures Offered to Participants during Genetic Counseling  
 All testing options were selected at least once, with NIPT being the most common 
choice (Figure 2.3).  The “other” category primarily refers to participants who pursued 
ultrasound only.  This information was obtained from the genetic counselor data 
collection form.    
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Figure 2.3 Participants’ Prenatal Genetic Testing Decisions 
A chi-square analysis was used to determine if participant demographic features 
influenced test selection.  One significant relationship was found:  participants who 
presented in second trimester were significantly more likely to opt not to have testing 
than participants who presented in first or third trimester, 2 (2, N = 104) = 11.363, p = 
.003.  No significant relationship was found between participant test selection and 
location, estimated household income, level of education, age at due date, or insurance. 
Possible differences in uptake of NIPT based on participant indication were 
evaluated.  No differences were found for those studied, including:  advanced maternal 
age, first trimester screen positive, second trimester screen positive, abnormal ultrasound 
results, family history of a genetic condition, and “other”.    
A chi-square analysis was performed to look for differences in the uptake of NIPT 
between participants in first, second, or third trimesters.  No significant difference was 
noted, 2 (2, N = 104) = 2.68, p = .262.  A similar analysis was performed to look for 
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differences in uptake of NIPT between the three study locations (Figure 2.4).  Greenville 
was noted to have the lowest uptake of NIPT, and Charleston to have the highest uptake, 
but no significant differences were observed, 2 (2, N = 105) = 3.23, p = .198.   
 
Figure 2.4 Uptake of NIPT by Study Location   
Participants were asked what other testing options they considered other than their 
decision.  Options included:  FTS, CVS, NIPT, MMS, Amniocentesis, Other, and Not 
applicable.  Using chi-square analysis, a significant difference was found between 
participants who chose NIPT and participants who did not in their consideration of CVS 
as a prenatal test, with participants who chose NIPT more likely to have considered this 
test, 2 (1, N = 95) = 4.16, p = .042.  However, upon further examination with Fisher’s 
Exact Test, no statistical significance was attributed to this factor (p = .054).  In addition, 
the factors first trimester screening, NIPT, MMS, amniocentesis, “other”, and “not 
applicable” were not noted to be significant. 
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2.4.3 Participant Resources used in Decision-making.  In total, 73% of 
participants responded “yes” to the question, “Before you saw the genetic counselor, did 
you have an idea of what your decision would be?”  When asked if their decision 
changed during the genetic counseling session, 82% of participants responded “no”.   
Participants were asked which of the following resources provided the most 
information to make their decision from the following:  Internet, Genetic counselor, 
Family/friend, General physician, OB/GYN, Partner, Other, Not applicable.  Some 
participants selected more than one answer, and these were included in analysis.  Most 
notably, 61% of participants felt their genetic counselor provided the most information, 
and 19% of participants felt their OB/GYN provided the most information.  A significant 
difference was not found between participants who selected NIPT and participants who 
did not select NIPT for the following:  internet, genetic counselor, family/friend, general 
physician, OB/GYN, partner, “other”, and “not applicable”.  A blank line was provided 
for participants to provide a response to the “other” option, and nine participants chose to 
do so.  Their responses were classified into thematic groups, as follows:  Healthcare 
resource (n = 2), Personal beliefs/values (n = 5), and Prior experience (n = 2).  
Participants were asked which resources were most helpful in making their 
decision.  Some participants selected more than one answer, and these were included in 
analysis.  In total, 68% of participants found their genetic counselor to be most helpful in 
making their decision and 13% of participants found their OB/GYN to be most helpful.  
No significant difference was found between participants who chose NIPT and 
participants who did not for the following: internet, genetic counselor, family/friend, 
general physician, OB/GYN, partner, other, not applicable. A blank line was provided for 
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participants to provide a response to the “other” option, and five participants chose to do 
so.  Their responses were classified into thematic groups, as follows: Prior experience (n 
= 1) and Personal beliefs/values (n = 4).   
In general, most participants did not find test recommendations from their 
OB/GYN, general physician, partner, or “someone else” to be important to their decision-
making process.  Of these options, participants most often found recommendations from 
their OB/GYN to be important, with 43% designating this choice as very important or 
somewhat important.  No significant difference was found between participants who 
selected NIPT and participants who did not select NIPT for the following: OB/GYN, 
general physician, and partner.   
  2.4.4 Factors that Influence NIPT Decision-making.  When asked to consider 
the relevance to their decision of the statement, “I would consider pregnancy termination 
if a chromosome condition is present,” the majority of participants (74%, n = 75) felt this 
was somewhat unimportant or very unimportant. One participant (1%, n = 1) expressed 
ambivalence by writing in and circling “2.5” between options “2” and “3” on a 1 through 
4 Likert scale question (Figure 2.5).   A chi-square analysis assessed the difference 
between participants who selected NIPT and participants who did not select NIPT, and no 
significant difference was noted, 2 (4, N =102) = 4.60, p = .330. 
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Figure 2.5 Participants’ Response to “I would consider pregnancy termination if a 
chromosome condition is present”.   
 
The majority of participants (58%, n = 58) regarded the statement, “I would not 
consider a pregnancy termination regardless of the test results” as very relevant or 
somewhat relevant to their decision.  One participant wrote in and circled “2.5” between 
options “2” and “3” on a 1 through 4 Likert scale question (Figure 2.6).   No significant 
relationship was found between participants who selected NIPT and participants who did 
not, 2 (4, N =100) = 3.54, p = .471.   
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Figure 2.6 Participants’ Response to “I would not consider a pregnancy termination 
regardless of the test results”.    
 
  A majority (91%, n = 95) of participants found the statement, “I want to be 
prepared if the baby had a disability,” to be either very important or somewhat important.  
A chi-square analysis was used to compare the response of participants who selected 
NIPT to participants who did not select NIPT, and a significant difference was observed, 
2 (3, N = 104) = 16.2, p = .001. Participants who chose NIPT were 1.3 times more likely 
to feel this factor was important to their decision than participants who did not choose 
NIPT.  Participants who did not choose NIPT were 8.2 times more likely than 
participants who chose NIPT to feel this factor was unimportant to their decision, though 
it should be noted that a small sample size was represented in this category (Figure 2.7). 
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Figure 2.7 Participants’ Responses to “I want to be prepared if the baby had a disability” 
(1=very important, 2=somewhat important, 3=somewhat unimportant, 4=very 
unimportant). 
 
When asked to respond to the statement, “I want to avoid the risk of miscarriage 
associated with some tests, the majority (88 %, n = 92) of participants felt this was very 
important or somewhat important.  A significant difference was not observed between 
participants who selected NIPT and participants who did not when chi-square analysis 
was performed, 2 (3, N = 104) = 6.51, p = .089.   
A majority (81%, n = 83) of participants considered obtaining genetic information 
about the fetus as early as possible in the pregnancy to be a very important or somewhat 
important factor in their prenatal test decision-making.  The differences between 
participants who selected NIPT and those who did not were assessed and a significant 
relationship was noted, 2 (3, N =103) = 11.0, p = .012, with participants who selected 
NIPT 1.5 times more likely than participants who did not select NIPT to feel obtaining 
genetic information about the fetus as early as possible was important.  Conversely, 
participants who did not select NIPT were 3.5 times more likely than participants who 
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selected NIPT to feel obtaining genetic information about the fetus as early as possible 
was unimportant  (Figure 2.8).   
  
Figure 2.8 Participants’ Responses to “I want to obtain genetic information about the 
fetus as early as possible” (1=very important, 2=somewhat important, 3=somewhat 
unimportant, 4=very unimportant).  
 
When asked to reflect on the statement, “I hope to learn the baby does not have 
any genetic conditions”, 86% (n = 87) of participants felt it was very relevant or 
somewhat relevant to their prenatal test decision.  No significant difference was noted 
between participants who chose NIPT and participants who did not, 2 (3, N = 101) = 
5.05, p = .168.   
A significant difference was observed between participants who chose NIPT and 
participants who did not in their response to the statement, “I chose my decision because 
this test provides more accurate information than other tests”, 2 (3, N = 102) = 9.32, p = 
.025.  Participants who selected NIPT were 1.4 times more likely than participants who 
did not select NIPT to feel this factor was important.  Conversely, participants who did 
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not select NIPT were 2.5 times more likely than participants who selected NIPT to feel 
this factor was unimportant (Figure 2.9).  In total, 77% of participants felt this factor was 
very important or somewhat important. 
 
Figure 2.9 Participants’ Response to “I chose my decision because this test provides more 
accurate information than other tests” (1=very important, 2=somewhat important, 
3=somewhat unimportant, 4=very unimportant). 
 
 Participants were asked about other test characteristics as well. When presented 
the statement, “I chose my decision because this test provides results in a shorter time 
span than other tests” 54% (n = 55) of total participants felt this was very relevant or 
somewhat relevant to their prenatal test decision.  No significant difference was found 
between participants who selected NIPT and participants who did not for the turnaround 
time of the test, 2 (3, N = 102) = 0.99, p = .802.   When asked to rate the importance of 
the statement, “The cost of the test was an important consideration,” 67% (n = 68) of 
participants found the statement to be either very unimportant or somewhat unimportant.  
In addition, 63% (n = 65) of participants found whether or not their insurance would pay 
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for the test to be very unimportant or somewhat unimportant.  No significant difference 
was found between participants who selected NIPT and participants who did not for the 
cost of the test, 2 (3, N = 102) = 2.61, p = .456, or insurance paying for the test, 2 (3, N 
= 103) = 2.08, p = .555.   
A blank line was provided for participants to provide factors they considered 
important; nine participants chose to do so.  Their responses were classified into thematic 
groups, as follows:  Concern about Down syndrome (3), Personal beliefs/values (1), 
Noninvasiveness/no risk of miscarriage (2), Accuracy of test (2), Gender (1), and Prior 
risk estimate (1).   
In conclusion of this section, a graph was made to depict the factors that 
influenced the selection of NIPT (Figure 2.10).  Three factors were found to be 
significantly more important to participants who selected NIPT than participants who did 
not.  “Other” was also found to be a significant factor, but was not included in the graph, 
as responses to this factor were often unrelated to each other. 
 
Figure 2.10 Factors Significantly More Important to Participants who Selected NIPT than 
Participants who did Not 
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Another graph was formulated to depict the top five factors of importance to total 
participants in the study (Figure 2.11).  Participant response is reported as total 
participants (blue), participants who selected NIPT (red), and participants who did not 
select NIPT (green).  Factors that were significantly more important to participants who 
selected NIPT than to participants who did not are designated with a white asterisk.   
 
Figure 2.11 Top Five Factors Most Frequently Rated as Important by Participants  
2.4.5 Open-ended Response.  The final question of the survey tool was an open-
ended response question asking participants if they had any thoughts or comments about 
their decision-making process that they would like to add.  A total of ten participants 
responded to this question; seven responses were relevant to the decision-making process 
are depicted below in Table 2.2.  One response is used in two thematic groups.   
Table 2.2 Participant Responses to Open-response Question 
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Thematic 
Group 
Sub-Group Participant Responses 
Information 
Genetic 
Counselor 
[Genetic Counselor] made all of this so easy. Information 
was explained so that we could understand everything 
Grateful for having to make my own decision and grateful 
for the informative information from the genetic 
counselor. 
I didn't know anything about a non-invasive prenatal test 
until today. 
Preparation 
I want as much information as possible just in case my 
baby do have down syndrome but it will not change the 
outcome. 
Personal 
Beliefs/ 
Values 
Religious 
God is in control! 
In the Book of Psalm: I 
Will Not 
Terminate 
This child will be loved, regardless of the ultrasound 
results. 
I want as much information as possible just in case my 
baby do have down syndrome but it will not change the 
outcome. 
 
2.5 Discussion 
Since inclusion criteria for this study stated participants must be offered NIPT 
during genetic counseling, all participants were offered this test.  Incidentally, this study 
consisted of a high-risk population.  Indications for NIPT (and thus for participation in 
this study) currently include:  advanced maternal age, an abnormal maternal serum 
screen, personal or family history of aneuploidy, or an abnormal ultrasound (Wilson et 
al., 2012).  
However, not every testing option was offered during every genetic counseling 
session.  This was not secondary to the study, but a function of appropriate clinical 
testing.  Testing options were offered based on participant gestational age and indication.  
Amniocentesis was offered during almost every session.  While amniocentesis can only 
be performed in second trimester, it is the most accurate diagnostic test available, so 
48 
 
patients were made aware of this test whether they presented during first or second 
trimester.  Conversely, multiple marker screening (MMS) is less accurate than first 
trimester screening (FTS) and is performed later in gestation, so MMS was not usually 
discussed if patients presented in first trimester.  Some tests, such as FTS and chorionic 
villus sampling (CVS) can only be performed during first trimester, and as such were not 
discussed if patients presented in second trimester.      
Most participants indicated their genetic counselor provided the most information 
and was most helpful during their decision-making process.  This suggests positive 
participant perception of prenatal genetic counseling and that genetic counselors played 
an integral role in participant selection of prenatal testing.  Interestingly, a majority 
(73%) of patients had an idea of what their decision would be before genetic counseling, 
and of these, most (82%) did not change their decision during the genetic counseling 
session.  As an overwhelming majority of participants elected to have NIPT, it seems 
unlikely that such a high percentage of participants were aware of the newest test before 
genetic counseling.  However, it is likely they were familiar with the qualities they were 
seeking in prenatal testing, and had therefore formulated an idea of what type of testing 
(eg. noninvasive, screening, etc.) they would prefer, even if they were unaware of NIPT 
until genetic counseling.  Some participants may have heard of NIPT from their 
OB/GYN.  Almost half (43%) responded that a suggestion from their OB/GYN was 
important to their decision, which supports similar findings by the 2011 study of pregnant 
women’s interest in NIPT and physician influence by Tischler et al.    
Noninvasive prenatal testing was selected over six times more frequently than any 
other test.   Interestingly, no difference in uptake of NIPT based on indication was noted. 
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One might have expected participants with abnormal ultrasound results to be less inclined 
to select NIPT, as NIPT detects aneuploidy only and is unable identify other potential 
causes for ultrasound anomalies.  Invasive diagnostic procedures would supply more 
information about potential causes for ultrasound anomalies because testing for single 
gene conditions as well as chromosomal abnormalities is available.  Yet participants with 
abnormal ultrasound results did not express particular interest in invasive diagnostic 
testing; of seven participants with ultrasound anomalies, one selected CVS and none 
selected amniocentesis.    
  2.5.1 Top Five Important Factors and Three NIPT-Selection Factors.  The top 
five factors most frequently rated as important by participants were selected for 
discussion (Figure 2.11).  Three factors were found to influence selection of NIPT, 
meaning these factors were significantly more important to participants who selected 
NIPT than to participants who did not (Figure 2.10).    
The overall factor participants (91%) selected most often as important to test 
selection was the desire to be prepared if the baby had a disability.  This was an NIPT-
selection factor, as well.   In the event of a positive test result, prospective parents may 
use this knowledge to prepare emotionally, make an appropriate delivery plan, and 
assemble a medical management team (Benn & Chapman, 2010).   
Current literature suggests women consider genetic testing to be pointless if they 
would not terminate in light of a positive testing result (Reid, Sinclair, Barr, Dobbs, & 
Crealey, 2009). Yet other women consider genetic testing to be empowering, even if they 
would not terminate an affected pregnancy.  For example, a study that surveyed parents 
of children with Down syndrome found 75% were disinclined to terminate a future 
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affected pregnancy, but only 33% would not have prenatal testing (Kuppermann et al., 
2011).  In our study, most participants who indicated termination of an affected fetus was 
irrelevant to their decision-making process opted to have prenatal genetic testing.  Our 
participants valued having genetic knowledge of the fetus to prepare for a possible 
disability or health concern, even if they did not intend to use testing to alter the course of 
their pregnancy.   
Participants (81%) indicated they wanted genetic information about the fetus as 
early as possible.  This was both a top five factor and the most significant NIPT-selection 
factor.  Early detection presents many advantages for women with affected or unaffected 
pregnancies.  For example, early detection of unaffected pregnancies could allow for 
parental reassurance and for bonding to occur sooner (Newson, 2008).  As discussed 
above, most participants regard a positive result as an opportunity to prepare to have a 
baby with a disability.  If parents decide to terminate an affected pregnancy, the 
procedure may be both physically safer and psychologically less traumatic at an earlier 
gestational age (Benn & Chapman, 2010).   Understandably, NIPT presents an attractive 
option to participants who value obtaining genetic information about the fetus early in 
gestation.  With the capability of being performed as early as 10 weeks gestation, NIPT 
can provide genetic information earlier than most other prenatal tests. In addition, its 
availability is not restricted by a gestational time window like other prenatal testing 
options (Lo, 2012).   
It has been suggested that NIPT may encourage termination of affected 
pregnancies without thoughtful reflection because the test provides results early in 
gestation, perhaps before parents have bonded with the fetus or publicly shared the 
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pregnancy (Skotko, 2009).  Although participants in our study were unaware of the 
genetic status of their fetus, their pre-test response did not support this speculation.  
While the majority of participants who selected NIPT felt obtaining genetic information 
early in gestation was important, most indicated termination of an affected fetus was 
irrelevant to their decision.  Furthermore, participants who selected NIPT were 1.3 times 
more likely to find being prepared if the baby had a disability important than participants 
who did not select NIPT.    
A majority of participants (86%) indicated the desire to learn the baby did not 
have any genetic conditions was important.  This factor was a top five factor but was not 
an NIPT-selection factor.  As discussed above, patients may seek this affirmation because 
a negative test result can provide reassurance and guide expectations and planning 
(Newson 2008).  
Many participants (77%) indicated they chose their test because it provided more 
accurate information than other tests.  This factor was both a top five overall factor and 
an NIPT-selection factor.   Of course, NIPT is not more accurate than amniocentesis or 
CVS, but it is more accurate than screening tests.  Thus, because this factor was 
significantly important to participants who selected NIPT, we can infer its ability to 
provide more accurate information than screening tests increased its uptake in our study.  
A related question on the study tool asked participants which testing options they also 
considered when making their decision.  We wondered whether participants who selected 
NIPT would more frequently consider invasive diagnostic testing (due to the increased 
accuracy of the test) or screening (no associated risk of pregnancy loss).  However, no 
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specific test was considered significantly more often than any other by participants who 
selected NIPT.   
The majority of participants (88%) indicated avoiding risk of miscarriage 
associated with invasive testing was important to their decision.  This factor was one of 
the top five factors but, surprisingly, was not an NIPT-selection factor.  It has been 
postulated that for many women the miscarriage risk associated with invasive testing is a 
psychological barrier to diagnostic testing and that if this risk were removed, women may 
feel more inclined to have a diagnostic test (Newson, 2008).  To be clear, NIPT results 
are not considered diagnostic, but NIPT does remove the risk of miscarriage and gives 
near-diagnostic results.  The majority of participants indicated learning genetic 
information about the fetus was important to them; thus, it would seem participants who 
wanted this information and to avoid risk of miscarriage would be motivated to pursue 
NIPT.  However, avoiding risk of miscarriage was not significantly more important to 
participants who selected NIPT than participants who did not.  We attempt to explain this 
phenomenon as follows:  some participants who pursued invasive diagnostic testing 
indicated that ‘avoiding risk of miscarriage’ was an important factor in their decision-
making process, even though they selected a test associated with risk of miscarriage.  
This suggests that although the desire to avoid risk of miscarriage influenced their 
decision, other factors were more important determinants.   
This brings up an interesting point about the clinical utility of NIPT.  The rapid 
advancements and high sensitivity of the test has called to question whether it may be 
used for diagnostic purposes. Current guidelines, however, maintain NIPT should be 
considered an advanced screening test (Devers et al., 2013).  Thus, a relevant role 
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remains for invasive diagnostic tests.  Our study indicates participants (at least some) 
perceive this difference and make decisions accordingly.  They recognize that NIPT, 
while very advanced, does not provide as accurate nor as comprehensive information as 
CVS or amniocentesis and opted to have an invasive procedure associated with risk of 
miscarriage, although avoiding risk of miscarriage was important to them.     Current 
literature has broached the possibility that the risk-free and simple process of NIPT will 
lead to the routinization of the test, but our study suggests this was not applicable to (at 
least some of our) participants’ decision making processes (Deans & Newson, 2011).  
They saw value in the role of invasive diagnostic testing, despite the associated risk of 
miscarriage and invasive procedure.  
  2.5.2 Limitations.  The sample size of our study was small and representative 
only of one geographic area.  In general, women in South Carolina are much less likely to 
terminate a pregnancy than women across the nation  (Centers for Disease Control and 
Prevention, 2011).  This was supported by our study, as most participants indicated 
avoiding termination was an important factor, but it should be noted that this population 
is not representative of all women.  Our survey did not address every possible factor that 
could influence participant decision-making.  For example, we did not ask about expected 
pain related to invasive procedures or the influence of religious beliefs (although several 
patients commented on the importance of their beliefs/values in the open-ended 
response).  Though we requested patient indication, we did not request specific risk 
estimates for advanced maternal age or screen positive results.  A further limitation of our 
study was that we did not inquire what prenatal genetic testing participants had received 
54 
 
for their current pregnancy prior to genetic counseling, and whether they had ultrasound 
before or after genetic counseling.   
2.5.3 Areas for Future Research.  Our study surveyed pregnant women in three 
cities in South Carolina about their prenatal testing decisions.  Future research may use a 
similar survey tool on participants in a different geographical area to observe the 
difference in prenatal test decision-making.  Another future study could develop a survey 
to be completed by patients upon receiving NIPT results.  It would be especially 
interesting to record invasive diagnostic procedure uptake and termination rates for 
patients with positive NIPT results.  
It is predicted that NIPT may soon be offered to women with low risk pregnancies 
(Norton et al., 2012).  If this becomes reality, an interesting follow-up would be to repeat 
this study using women of the general population, instead of women with high risk 
pregnancies only. The majority of participants in the current study were of advanced 
maternal age, meaning their pregnancies had increased chance for aneuploidy; however, 
the majority of pregnant women in a study of the general population would not be 
advanced maternal age or have this increased risk of aneuploidy.  Not having this 
inherent elevated risk may affect their decision-making process. 
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Chapter 3. Conclusions 
 Patients are faced with new decisions as NIPT is integrated into prenatal testing.  
This study discussed the top five factors most frequently rated as important by 
participants about their prenatal testing decision and identified three NIPT-selection 
factors.  Participants tended to want testing to be prepared if the baby had a disability, to 
avoid the risk of miscarriage, to be reassured the baby was unaffected, to obtain fetal 
genetic information as early as possible, and to have a test that provides more accurate 
results than other tests.  Participants who selected NIPT were significantly more likely to 
want to obtain fetal genetic information as early as possible, to have a test that provides 
more accurate information than other tests, and to be prepared if the baby had a disability.  
While every patient should be counseled as a unique individual, the results from this 
study are observations that may help healthcare providers better understand patient 
perspective.  This study reveals five factors important to patient decision-making 
regarding prenatal testing; of these, three factors (obtaining genetic information about the 
fetus as early as possible, having a test that provides more accurate information than 
other tests, and being prepared if the baby had a disability) were significantly influential 
in patient selection of NIPT.   
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Appendices 
Appendix A: Patient Survey 
 
Dear patient,  
 
Thank you for your interest in our research study.  The purpose of our research is to 
examine how women make decisions regarding prenatal testing.  This survey should take 
about 10 minutes to complete, and it may be returned to your genetic counselor or mailed 
in the return envelope provided.  Any questions or concerns regarding this research may 
be directed to Kim Hamann, principle investigator, at (859) 803-3437 or Janice Edwards, 
project advisor, at (803) 545-5706.  Questions about rights as a research participant may 
be directed to the Office of Research Compliance at the University of South Carolina at 
(803) 777-7095 or the Office of Research Integrity at the Medical University of South 
Carolina at (843) 792-4148. 
 
Participation is voluntary and confidential. You may skip any questions you do not want 
to answer.  Your genetic counselor will complete a short data collection form about your 
testing options and preferences.   
 
The questions in this survey often reference “your decision”. You might have decided: 
 To have a specific prenatal test 
 Not to have more prenatal testing 
 Or,  you might not have decided yet  
 
Whatever choice you make is the right one for you and your genetic counselor supports 
your decision.  Please reflect on your decision-making process in the following questions: 
 
 
 
Reflecting on your decision… 
 
1. Before you saw the genetic counselor, did you have an idea of what your decision 
would be?  
a. Yes 
b. No   (If you answer no to Question #1, please skip to question #3.) 
 
2. Did your decision change during genetic counseling? 
a. Yes 
b. No 
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3. Which resource provided the most information to make your decision?  
a. Internet 
b. Genetic counselor 
c. Family/friend  
d. General physician 
e. OB/GYN 
f. Partner 
g. Other____________________________________________________ 
h. Not applicable 
 
4. Which resource was most helpful in making your decision? 
a. Internet 
b. Genetic counselor 
c. Family/friend  
d. General physician 
e. OB/GYN 
f. Partner 
g. Other__________________________________________________ 
h. Not applicable 
 
5. When you were making your decision, did you consider any other options?  If so, 
please circle all that apply. 
a. First trimester screening 
b. CVS 
c. Non-invasive prenatal testing 
d. Multiple marker screening 
e. Amniocentesis 
f. Other _________________________________ 
g. Not applicable 
 
Considering your decision-making process… 
 
Please consider the following statements and rate their importance to your decision as 
you were presented different testing options, where 1 is very important and 4 is very 
unimportant: 
 
 
 
 
6. Whether or not my insurance company would pay for the test was an important 
consideration 
1  2  3  4  
  
 
Very important        Very unimportant   
1   2   3   4 
  
 
64 
 
7. The cost of the test was an important consideration   
1  2  3  4 
 
8. I want to obtain test results before I tell others I am pregnant 
1  2  3  4   
  
9. I wish to know nothing about the genetic makeup of the baby 
1  2  3  4   
 
10. I want to be prepared if the baby had a disability 
1  2  3  4   
 
11. I want to avoid the risk of miscarriage associated with some tests 
1  2  3  4   
 
12. I want to obtain genetic information about the pregnancy as early as possible 
1  2  3  4   
 
13. Other factors that were important to your decision may be listed below 
__________________________________________________________________ 
1  2  3  4   
 
 
 
Please consider the following statements and rate their relevance to your decision as you 
were presented different testing options, where 1 is very relevant and 4 is very irrelevant: 
 
 
 
 
 
14. I  had a positive screening test and am concerned that a chromosome condition 
may be present 
1  2  3  4  
 
15. I would consider pregnancy termination if a chromosome condition is present 
1  2  3  4   
 
16. I chose my decision because this test provides more accurate information than 
other tests 
1  2  3  4 
 
17. I chose my decision because this test provides results in a shorter time span than 
other tests 
1  2  3  4 
 
Very relevant        Very irrelevant   
1   2   3   4 
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18. My OB/GYN suggested this decision, which heavily influenced my decision 
1  2  3  4   
 
19. My general physician suggested this decision, which heavily influenced my 
decision 
1  2  3  4 
 
20. My partner suggested this decision, which heavily influenced my decision 
1  2  3  4 
 
21. Someone else suggested this decision, which heavily influenced my decision 
1  2  3  4 
 
22. I would not consider pregnancy termination regardless of test results 
1  2  3  4 
 
23. I hope to learn the baby does not have any genetic conditions 
1  2  3  4 
 
24. Other____________________________________________________________ 
1  2  3  4 
 
 
A couple more questions about you… 
 
1. How old will you be at the expected due date? ________________ 
 
2. How many weeks pregnant are you? ______________________ 
 
3. Please list your insurance provider. _______________________ 
 
4. Please estimate your annual household income 
a. Below $20,000 
b. $20,000-$50,000 
c. $50,000-$80,000 
d. $80,000-$110,000 
e. Above $110,000 
 
5. What is your highest completed level of education? 
a. Less than high school 
b. High school/GED 
c. Associate’s degree 
d. Master’s degree 
e. Advanced degree 
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A Final Question 
 
If there are any thoughts or comments about your decision-making process that you 
would like to add, please do so in the space below: 
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Appendix B: Genetic Counselor Data Collection Form 
Please answer the following in regards to your patient… 
 
1. Which of the following indications prompted the patient’s visit to genetic 
counseling?  (Circle all that apply.) 
a. Maternal age greater than 35 
b. First trimester screening was positive for trisomy 21, 18, or 13 
c. Second trimester screening was positive for trisomy 21 or 18 
d. Abnormal ultrasound findings 
e. Family history of 
_________________________________________________ 
f. Other 
__________________________________________________________ 
 
2. The gestational age of the patient was ________ weeks at the time of genetic 
counseling. 
 
3. Which of the following procedures was offered to the patient during this session? 
(Circle all that apply.) 
a. First trimester screening 
b. CVS 
c. Non-invasive prenatal testing 
d. Multiple marker screening 
e. Amniocentesis 
f. Other 
___________________________________________________________ 
 
4. Which of the following has the patient chosen at this time?  Only select the 
method she is currently pursuing.  (Do not select a screening test if she has 
already had one for this pregnancy.) 
a. First trimester screening 
b. CVS 
c. Non-invasive prenatal testing 
d. Multiple marker screening 
e. Amniocentesis 
f. Has decided not to pursue any testing 
g. Has not decided 
h. Other __________________________________ 
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Appendix C: Statistical Analysis Results 
Table C.1 Factors Influencing NIPT Selection 
Indication χ2 df n p-value 
 Advanced Maternal 
Age 
0.868 1 105 0.351 
Positive First 
Trimester Screen 
0.837 1 105 0.360 
Positive Second 
Trimester Screen 
0.072 1 105 0.788 
Abnormal Ultrasound 
Results 0.003 
1 105 0.954 
Family History of 
Genetic Condition 
0.041 1 105 0.840 
Other 1.31 1 104 0.252 
Testing Options χ2 df n p-value 
First Trimester 
Screening 
0.076 1 95 0.783 
CVS 4.16 1 95 0.042 
NIPT 0.022 1 95 0.883 
MMS 2.68 1 95 0.102 
Aminocentesis 2.99 1 95 0.084 
Other 0.040 1 95 0.841 
Not Applicable 0.455 1 95 0.500 
Most Information χ2 df n p-value 
Internet 0.207 1 102 0.649 
Genetic Counselor 0.660 1 102 0.416 
Family/Friend 0.119 1 102 0.730 
General Physician 0.441 1 102 0.507 
OB/GYN 0.016 1 102 0.901 
Partner 1.16 1 102 0.282 
Other 0.026 1 102 0.872 
Not Applicable 0.013 1 102 0.910 
Most Helpful χ2 df n p-value 
Internet 0.030 1 102 0.863 
Genetic Counselor 0.050 1 102 0.823 
Family/Friend 0.062 1 102 0.803 
General Physician 0.409 1 102 0.552 
OB/GYN 0.669 1 102 0.413 
Partner 0.007 1 102 0.932 
Other 0.030 1 102 0.863 
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Not Applicable 2.46 1 102 0.117 
Demographics χ2 df n p-value 
Location 3.239 2 105 0.198 
Estimated Annual 
Household Income 
8.551 4 100 0.073 
Level of Education 2.167 4 104 0.705 
Trimester 2.682 2 104 0.262 
Age at Due Date 35.767 36 102 0.480 
Insurance 3.476 2 77 0.176 
Suggested Decision χ2 df n p-value 
OB/GYN 2.319 3 100 0.509 
General Physician 2.247 3 95 0.523 
Partner 2.306 3 98 0.511 
Someone Else 1.937 3 99 0.586 
     
Table C.2 Demographic Features Influencing Participant Decisions Not to have Testing 
No Testing 
Demographics χ2 df n p-value 
Trimester 11.363 2 104 0.003 
Age at Due Date 17.474 25 104 0.864 
Insurance 0.449 2 102 0.799 
Estimated Annual 
Household Income 
3.086 4 100 0.544 
Level of Education 0.959 4 104 0.916 
 
 
